ANALGE S IC E FFE CT OF LAR IMS H™ IN S E R IE S OF E LE VE NC HR ONIC A R T HR IT IS PAT IE NT S

M. de la R osa-V iejo, R . R odríguez-P érez, H.Lemus-B alcazar, M. G arcía-Montañéz and

M.D. R amírez-G onzález

Hospital of Mother T heresa of C alcuta-México, F ascimex S .A., National

Autonomous Univers ity of Mexico,Depts . of P hys iology and P harmacology

T he word –arthritis - literally means joint inflammation, but it is often used morebroadly to indicate any of the more than 100 chronic diseases of joints , bonesand muscle. Two of the most common and best known types of arthritis areOsteoathritis , a form of cartilage waist in the joints , and R heumatoid Arthritis , animmune system disease, that causes pain and disability as the result of jointinflammation. (1)

A rthritis a ffe c ts two time s morewomen than men, it is also the rea-son of 39 million medical consults andmore than one million hospilalizationseach year, the estimated cost of ar-thritis to the economy is more than 64billion dollars . (2)

T here is no cure for most of the differ-ent types of arthritis . It’s been told thanmany forms of arthritis response to anwide ra nge of conventiona l trea t-ments , automeditation and alternativetherapies , but nothing conclus ive. (2)

In the treatment of this diseases with different drugs like: NS AIDs (Non steroidealaintiinflammatory drugs), DMAR Ds (Disease-modifying antirheumatic drugs),S teroids , Inmunosuppresors , S alicylates and Analges ics , is found that in mostof them there are contraindications and nocive effects , specially damage of thegastrointestinal system, bas ically gastritis and ulcers . (3)

INT R ODUC T ION

LAR IMS H™ (LR ) is a Mexican Hydrocarbon product obtained via catalytic dis -tillation from crude oil. It contains 345 different compounds , among others : Al-kanes (P entadekanes , hepta and octadecanes), alkanes-Isoprenoids (pris taneand phytane), cycloparafins (naphtenes : cyclopentane, cyclohecane, decalin),aromatics , nitrogen-oxygen-sulphur coumpounds. T he main characteristics are:average molecular weight: 250, sulphur content: 1.5% max., carbon: 85%, hy-drogen: 13%, nitrogen: 0.03% and oxygen: 0.4%.

T he hydrocarbon fraction is further-more formulated with several com-pounds that contains chemical ele-ments from the fourth a nd s ixthgroups of the P eriodic Table of theE lements , then applies a radiationprocess with UV. (4)

S tudies for the lethal effect of LR andits effects on body weight, food andwa ter inta ke following a cute a nd

chronic treatment when given in different doses (0.001 to 30 g/kg) and routes ofadministration (topic and oral) to C D-1 male mice with an average body of 44 g.Lethal dose in mice was 21 g/kg (C .L. 10.94 - 41.2) which indicate a wide mar-gin of safety for this product. No change in body weight occurred with dailytreatment up to 73 days with LR treatment. A s ignificant loss of body hair (over90% of the total fur) was observed by day 45th. T he alopecia was reversedwithin three weeks when LR treatment was discontinued. F ood and water in-take were s ignificantly increased with greater effect observed with topic LR ( +vs + , P <0.05). E stimates of lethal dose in rats and mice (18 and 20 g/kg,respectively) indicate a wide margin of safety for this product.

(P atent registration number of LAR IMS H™ ; PA/a/2001/010282)

L A R IMS H P roduc t

T he objective of the present work is to evaluate the effect ofLAR IMS H™ in pacients with R heumatoid Arthtitis and Osteoar-thritis trated with diverse types of drugs within the last 5 yearsand did not achieve an appropiate response for pain control,joint displacement disability and joints deformed.

OB J E C T IV E S

P ain evaluation in patients was carry out us ing the Huskisson test. B riefly, thistest is carry out us ing an analogous 10 cm. visual scale (horizontal or vertical),with an end labeled with “Without P ain” and the opposite end labeled with “P ainas high as poss ible”, has great sens ibility and ability to reproduce in the quanti-fication of joint pain magnitude for patients with R heumatoid Arthritis , when thepatient is asked to point over the line his pain intens ity. T his has been proveenin several s tudies , that is why it is so widely used. (5,6)

T he clas ic scheme for a visual scale of 10 cm. long is shown.

P atient s elf-evaluated pain

ME T HODS

Walk dis abilityT he walk disability had been evaluated acordingto an modified vers ion of the Health AssesmentQuestionaire – Disability Index (HAQ-DI), in thespanish version of the questionaire (S panish-HAQ-DI). (5)

E ach patient receive 1 ml. orally and 2 ml. topi-cal of LAR IMS H during the evaluation time.

R E S ULT SIn the Table, the effect of LAR IMS H in P ain and Walkdisability is analized for chronic arthritis patients withan average age of 67 years and 13 years of deseaseevolution and including 10 female and one male.

In the P ain scale and Walk limitation evaluation as ignifican decrease of pain of a 62% (8 vs 3, P <0.05,n=11) and a decrease in the Walk limitation from80% to a 25% is shown.

C ONC L US ION

T he lack of success for the conventional medicine and their unwanted s ide-effects are causes for interrupt and/or irregularities in the medical treatments ofthe Arthritis . The s ignificative results with LAR IMS H in the treated patients showsthat exists a great pos ibility for this alternative treatment in these rheumaticdiseases , with almost null s ide effects .

WithoutPain

Pain as high aspossible

(1) An Overview of Arthritis and R ealted Disorders , C olorado Healths ite,http://www.coloradohealthnet.org/arthritis /arth_over.html(2) What is Arthritis? , Arthritis Web S ite,http://www.arthirtiswebsite.com/heath_library/bas ics/what_is .html(3) E vans J MM, McMahon AD, McG ilchrist MM, et al. Topical non-steroideal anti-inflammatory drugs and admiss ion to hospital for

upper gastrointestinal bleeding and perforation: A record linkage case-control s tudy. B MJ 331:22-26, 1995(4) R odriguez R , G arcía M, E fecto de fracciones hidrocarbonadas combinadas con metales activos sobre la disminución del dolor en

pacientes con cáncer, XXI C ongreso Nacional de C iencias F is iológicas (O-62) Qro. Qro, 14-08-1998(5) F rancisco R amos Niembro, E nfermedades R eumáticas , C riterios y Diagnósticos , E d. Mc G raw-Hill Interamericana, 1999, pp. 15-

47(6) Huskisson E C , Meassurement of pain. Lancet. 1974; ii:1127-1131(7) Arthritis F oundation, Alternative T herapies , Arthritis F oundation Web S ite, http://www.arthritis .org/alttherapies/(8) B oers M, Tugwell P, F elson DT, et al. World Head Organization an the International League of Association for R heumatology core

E ndpoints of symptoms modifying antirheumatic drugs in rheumatoid arthritis clinical trains , J ournal of R heumatology, 1994; 21(S uppl.41): 86-89

(9) C allahan LF, B rooks R H, S ummey J A, et al. Quantitative pain assesment for routine care of rheumatoid arthritis patients , us ing apain scalebased on activitiesof daily living and visual analog pain scale. Arthritis R heum. 1987; 30:630-636

(10) Debra F Lappin. Arthritis : What We K now Today. S cientific Workshops , C onferences , and C ommittees R eports . F riday, May 30,1997. http://www.niams.nih.gov/ne/reports/sci_wrk/1997/lappin.htm

(11) E lliot D R osenstein, Agentes tópicos en el tratamiento de las enfermedades reumáticas . R heumatic Disease C linics of NorthAmerica (E dición española). 1999; 4:913-930

(12) E scalante A, G alarza-Delgado D, B eardmore T D, et al. C ross-cultural adaptation of a brief outcome questionnaire for spanishspeaking arthritis patients . Arthritis R heum. 1996; 39: 93-100

(13) What is it? , Arthritis Web S ite,http://www.arthirtis webs ite.com/facts /form/oa.js p

R E F E R E NC E S

T R A D I T I O N A L T R A D I T I O N A L + L A R I M S H

L A R I M S H O N L Y

B E F O R E L A R I M S H

A F T E R L A R I M S H

B E F O R E L A R I M S H

A F T E R L A R I M S H

1 F 7 3h o m e - w a s h e r -

i r o n e r O Ak n e e s

f i n g e r s

h a n d s2 n a p r o x e n -

O r a l : 1 T o p i c a l : 2 8 2 7 0 % 2 0 %

2 F 8 7h o m e - w a s h e r -

i r o n e r O A

k n e e s

e l b o w s s h o u l d e r s

l u m b a r v e r t e b r a e

1 5d i c l o f e n a c o ,

i n d o m e t a c i n a -O r a l : 1

T o p i c a l : 2 9 4 8 0 % 3 0 %

3 F 5 4 t o r t i l l a m a k e r O Ah a n d s

s h o u l d e r s 2 d i c l o f e n a c o -O r a l : 1

T o p i c a l : 2 6 2 - -

4 F 5 3 o f f i c e s e c r e t a r y R Ak n e e s

e l b o w s h a n d s

1 5m e t o t r e x a t e ,

c l o r o q u i n a , k n e e s u r g e r y

-O r a l : 2

T o p i c a l : 2 1 0 5 9 0 % 4 0 %

5 F 6 7h o m e - w a s h e r -

i r o n e r R A

h a n d s

f i n g e r s e l b o w s

s h o u l d e r s

2 4

m e t r o t e x a t e ,

c l o r o q u i n a , h a n d s u r g e r y

( 7 t i m e s )

-O r a l : 2

T o p i c a l : 2 1 0 2 9 0 % 2 0 %

6 F 5 2h o m e - w a s h e r -

i r o n e r R Ah a n d s

k n e e s h i p

a n c l e s3 4

d i c l o f e n a c o ,

i n d o m e t a c i n a , p a r a c e t a m o l ,

n a p r o x e n o ,

m e t o t r e x a t e , c l o r o q u i n a , g o l d

s a l t s

m e t i c o r t e n ,

p l a q u e n i l , d i l o t e n , l a r i m s h

O r a l : 1 T o p i c a l : 2 7 1 8 0 % 1 0 %

7 M 7 6 w a l k i n g s a l e s O A

k n e e s

a n c l e s l u m b a r

v e r t e b r a e

1 5d i c l o f e n a c o ,

n a p r o x e n , i n d o m e t a c i n a

-O r a l : 1

T o p i c a l : 2 9 4 9 0 % 2 0 %

8 F 7 7h o m e - w a s h e r -

i r o n e r O A

h a n d s

k n e e s l u m b a r

v e r t e b r a e

1 7

n a p r o x e n , d i c l o f e n a c o ,

p a r a c e t a m o l ,

a s p i r i n

-O r a l : 1

T o p i c a l : 2 7 2 5 0 % 1 0 %

9 F 6 5h o m e - w a s h e r -

i r o n e r O A

k n e e s

c e r v i c a l d o r s a l

l u m b a r v e r t e b r a e

5n a p r o x e n ,

d i c l o f e n a c o ,

a s p i r i n-

O r a l : 1 T o p i c a l : 2 8 4 8 0 % 4 0 %

1 0 F 7 2h o m e - w a s h e r -

i r o n e r O Ak n e e s

h a n d s 5n a p r o x e n ,

d i c l o f e n a c o ,

a s p i r i n-

O r a l : 1

T o p i c a l : 2 8 3 8 0 % 3 0 %

1 1 F 6 3w a s h e r - i r o n e r -

d r y c l e a n e r O Ak n e e s h a n d s 1 0 d i c l o f e n a c o -

O r a l : 1 T o p i c a l : 2 7 3 6 0 % 2 0 %

P A I N S C O R E S W A L K D I S A B I L I T Y ( % )T R E A T M E N T S# S E X A G E E M P L O Y M E N T D I A G N O S I S A F F E C T E D J O I N T S

E V O L U T I O N O F D I S E A S E

( y e a r s )